Fig. 2From: Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patientsDensity distribution of fluorescence intensity values. The distribution, range and frequency of relative fluorescence intensity units (RFU) of proteins detected in all 47 patient samples in the (a). Discovery assay and (b). SOMAscan assay are shownBack to article page